John Blankenship Email and Phone Number
John Blankenship work email
- Valid
- Valid
- Valid
John Blankenship personal email
Protein and antibody engineer with 16+ years of experience at drug discovery and development. Led antibody discovery campaigns against multiple classes of antigens. Developed and implemented novel bispecific antibody technologies for the treatment of oncology and autoimmune disease, as well as high-throughput approaches to antibody expression and screening. Successfully led bispecific antibody project from discovery to IND, and also led additional biologic projects (bispecifics, ADCs, vaccines) from discovery to non-clinical testing. Familiar with pre-clinical, non-clinical, CMC, and regulatory challenges specific to complex biologic and empowered antibody (ADCs, bispecifics, multispecifics, RLT) development, and experienced working across functions and with external collaborators. Specialties:* Antibody discovery (display approaches, hybridoma generation), protein/antibody engineering, phage display, molecular biology, protein expression/purification, antibody humanization, affinity maturation, antibody stabilization, bispecific antibody engineering* Biophysical analysis (CD, Fluorescence, and Mass Spectroscopies; Biacore/SPR; ITC; DSC; Analytical Ultracentrifugation) and developability assessments* In vitro assay development (ELISA, Biacore/SPR, FRET), high throughput screening, automation* In vitro cellular assay development; cytotoxicity, migration, invasion assays, signaling reporter assays * research supervision of individual associates and research groups; preclinical project management; alliance management
Novartis
View- Website:
- novartis.com
- Employees:
- 79781
- Company phone:
- +41 61 324 11 11
- Company email:
- eric.althoff@novartis.com
-
Executive Director And Head, Biologics Discovery And AutomationNovartisBoston, Ma, Us
-
Executive Director And Head, Biologics Discovery & AutomationNovartis Jan 2024 - PresentBasel, Baselstadt, ChGlobal head of antibody discovery unit in the Biologics Research Center, leading groups working on antibody discovery, optimization and laboratory automation in the USA and Switzerland. Coordinating biologics discovery for all of Novartis's therapeutic areas. Initiated two external collaborations in generative AI/ML.
-
Executive Director And Head, Discovery TechnologiesNovartis Oct 2021 - Dec 2023Basel, Baselstadt, ChGlobal head of antibody discovery unit in the Novartis Biologics Center, leading groups working on antibody discovery, optimization, laboratory automation, and bioanalytical characterization in the USA and Switzerland. Coordinating biologics discovery for all of Novartis's therapeutic areas. Serving as project leader on multiple therapeutic projects.
-
Associate Director, Antibody DiscoveryNovartis Feb 2020 - Sep 2021Basel, Baselstadt, Ch
-
Senior Investigator Ii And Group Leader, Antibody DiscoveryNovartis Sep 2019 - Feb 2020Basel, Baselstadt, ChLeading antibody discovery across all of NIBR's therapeutic areas using both library-based and immunization-based approaches at NIBR's Cambridge campus. Serving as project leader on multiple therapeutic projects.
-
Senior Investigator Ii And Group Leader, Library TechnologiesNovartis Apr 2019 - Aug 2019Basel, Baselstadt, Ch
-
Senior Investigator And Group Leader, Library TechnologiesNovartis Jul 2018 - Mar 2019Basel, Baselstadt, ChLeading multiple phage display and yeast display labs for high-throughput antibody discovery across Novartis's therapeutic areas at NIBR's Cambridge campus. Serving as project leader on multiple therapeutic projects.
-
Senior Investigator And Lab Head, Therapeutic Antibody DiscoveryNovartis Feb 2017 - Jun 2018Basel, Baselstadt, ChLed a high-throughput antibody discovery and engineering group. Used phage display and yeast display to discover and optimize new therapeutic antibodies across multiple disease areas in Novartis. Served as project leader for multiple therapeutic projects.
-
Lead Scientist, Molecular Biology And Protein EngineeringAptevo Therapeutics Inc Aug 2016 - Jan 2017Seattle, Wa, UsManaged molecular biology and antibody engineering group at Aptevo Therapeutics in Seattle, after the spinout from Emergent BioSolutions. -
Lead Scientist, Molecular Biology And Protein EngineeringEmergent Biosolutions Jan 2014 - Aug 2016Gaithersburg, Maryland, UsManaged molecular biology and antibody engineering group at Emergent BioSolutions in Seattle. Led MOR209/ES414 project through IND filing, helped establish clinical collaborators and helped develop translational research plan for phase 1 study in mCRPC. Assisted with business development to secure a development partner for MOR209/ES414. Helped identify new oncology targets and initiated a new bispecific antibody project targeting ROR1 for the treatment of solid malignancies. Publications:* Molecular Cancer Therapeutics (2016), in press -
Principal Scientist, Applied ResearchEmergent Biosolutions Oct 2010 - Jan 2014Gaithersburg, Maryland, UsDemonstrated pre-clinical POC for bispecific antibodies redirecting T cell cytotoxicity towards targets in both solid and hematological malignancies. Led anti-PSMA x anti-CD3 bispecific antibody project (ES414) through in vivo POC in prostate cancer models, PK and repeat-dose toxicology studies in non-human primates, and prepared data package for Pre-IND meeting with FDA. Developed cell-based potency release assays for bispecific antibody projects.
-
Scientist Ii, Structural BiologyTrubion Pharmaceuticals Apr 2008 - Oct 2010UsUsed biophysical and protein engineering techniques in biologic drug discovery in AIID and oncology programs at Trubion. Worked on bispecifics that selectively target T-cell costimulatory pathways on antigen presenting cells, as well as bispecifics targeted at hematologic malignancies. Served as project leader for an oncology project using bispecific antibodies to target solid malignancies expressing the RON receptor tyrosine kinase, and initiated discovery efforts on PSMA-directed therapies.Presentations:"anti-CD79B x anti-DR ScorpionTM Molecule: A Single Chain, Bispecific Immunotherapeutic With Potent In Vitro Activity Against B Cell Lymphoma" - 2009 AACR"Beyond SMIPsTM: The Development of Small Multi-Specific Immunotherapeutics" - 2010 IBC Complex Biologic Development & Production"ScorpionTM Molecules Block T cell Co-stimulation via CD80/CD86 Blockade and Induce a Tolerogenic Response via an IL10 Agonistic Signal" - 2010 PEGS -
PostdocGenentech Jul 2006 - Apr 2008South San Francisco, California, UsWorking with Kurt Deshayes, in the Department of Protein Engineering, I used biophysical methods to determine the binding mode and mechanism of action of IAP antagonists to c-IAP1 and XIAP; also studied the role of IAPs as E3 ubiquitin ligases in apoptosis, including the discovery and characterization of a previously unknown UBA domain in the IAPs. Used phage display of protein and peptide libraries to find selective binders of proteins involved in NF-κB activation and the ubiquitin/proteasome system, towards the goal of developing novel inhibitors of protein-protein interactions. Publications:* Nature Structural & Molecular Biology (2014) 21, 1068-1074.* Biochemical Journal (2009) 417, 149-160.* Cell (2007) 131, 669-681. -
PostdocUniversite De Montreal Jun 2003 - Jun 2006Montréal, Qc, CaWith William Lubell (Univ de Montreal) and Uri Saragovi (McGill Univ) , I used computational and spectroscopic approaches to study novel antagonists and identify possible modes of binding to the oxytocin receptor, as well as novel antibody-derived ligands for the cancer-associated GD2 ganglioside. Helped design and used a Pictet-Spengler cyclization strategy to create a novel series of pyrrolo[3,2-d]pyrimidines.Publications:* Chemistry & Biology (2010) 17, 183-194.* Heterocycles (2008) 76, 1121-1131.* Science of Synthesis 21.11, Chemistry of Amides. (2005) 713-809.* Journal of Peptide Science. (2005) 11, 365-378.* Peptides (2004) 746-747.
John Blankenship Skills
John Blankenship Education Details
-
Scripps ResearchBiophysical Chemistry (Mcsc) -
University Of WashingtonBiochemistry
Frequently Asked Questions about John Blankenship
What company does John Blankenship work for?
John Blankenship works for Novartis
What is John Blankenship's role at the current company?
John Blankenship's current role is Executive Director and Head, Biologics Discovery and Automation.
What is John Blankenship's email address?
John Blankenship's email address is jo****@****tis.com
What schools did John Blankenship attend?
John Blankenship attended Scripps Research, University Of Washington.
What are some of John Blankenship's interests?
John Blankenship has interest in Environment.
What skills is John Blankenship known for?
John Blankenship has skills like Protein Chemistry, Drug Discovery, Biochemistry, Assay Development, Molecular Biology, Cell, Antibodies, Elisa, Structural Biology, Protein Protein Interactions, Protein Engineering, In Vitro.
Who are John Blankenship's colleagues?
John Blankenship's colleagues are Johanna Engels, Yücel Sin, Jean Allonas, Stefania Paparo, Senca Qian, Bo Mr, Ani Sergieva.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial